Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
2002 2
2004 3
2005 5
2006 3
2007 5
2008 3
2009 3
2010 3
2011 1
2012 2
2013 3
2014 5
2015 8
2016 5
2017 6
2018 4
2019 4
2020 3
2021 9
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

68 results
Results by year
Filters applied: . Clear all
Page 1
Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway.
Herbertz S, Sawyer JS, Stauber AJ, Gueorguieva I, Driscoll KE, Estrem ST, Cleverly AL, Desaiah D, Guba SC, Benhadji KA, Slapak CA, Lahn MM. Herbertz S, et al. Among authors: gueorguieva i. Drug Des Devel Ther. 2015 Aug 10;9:4479-99. doi: 10.2147/DDDT.S86621. eCollection 2015. Drug Des Devel Ther. 2015. PMID: 26309397 Free PMC article. Review.
[Asthma and obesity in childhood: what is the link?].
Deschildre A, Pin I, Gueorguieva I, de Blic J. Deschildre A, et al. Among authors: gueorguieva i. Arch Pediatr. 2009 Aug;16(8):1166-74. doi: 10.1016/j.arcped.2009.04.001. Epub 2009 May 12. Arch Pediatr. 2009. PMID: 19442499 Review. French.
A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma.
Kelley RK, Gane E, Assenat E, Siebler J, Galle PR, Merle P, Hourmand IO, Cleverly A, Zhao Y, Gueorguieva I, Lahn M, Faivre S, Benhadji KA, Giannelli G. Kelley RK, et al. Among authors: gueorguieva i. Clin Transl Gastroenterol. 2019 Jul;10(7):e00056. doi: 10.14309/ctg.0000000000000056. Clin Transl Gastroenterol. 2019. PMID: 31295152 Free PMC article. Clinical Trial.
Dramatic impact of morbid obesity on child lung development.
Hochart A, Nève V, Drumez E, Pigeyre M, Mallart A, Monaca C, Le Rouzic O, Gueorguieva I, Matran R. Hochart A, et al. Among authors: gueorguieva i. Arch Pediatr. 2021 Apr;28(3):186-190. doi: 10.1016/j.arcped.2021.02.016. Epub 2021 Mar 11. Arch Pediatr. 2021. PMID: 33714673
Randomized Phase 2 Studies of Checkpoint Inhibitors Alone or in Combination With Pegilodecakin in Patients With Metastatic NSCLC (CYPRESS 1 and CYPRESS 2).
Spigel D, Jotte R, Nemunaitis J, Shum M, Schneider J, Goldschmidt J, Eisenstein J, Berz D, Seneviratne L, Socoteanu M, Bhanderi V, Konduri K, Xia M, Wang H, Hozak RR, Gueorguieva I, Ferry D, Gandhi L, Chao BH, Rybkin I. Spigel D, et al. Among authors: gueorguieva i. J Thorac Oncol. 2021 Feb;16(2):327-333. doi: 10.1016/j.jtho.2020.10.001. Epub 2020 Nov 6. J Thorac Oncol. 2021. PMID: 33166722 Clinical Trial.
Phase II Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes.
Santini V, Valcárcel D, Platzbecker U, Komrokji RS, Cleverly AL, Lahn MM, Janssen J, Zhao Y, Chiang A, Giagounidis A, Guba SC, Gueorguieva I, Girvan AC, da Silva Ferreira M, Bhagat TD, Pradhan K, Steidl U, Sridharan A, Will B, Verma A. Santini V, et al. Among authors: gueorguieva i. Clin Cancer Res. 2019 Dec 1;25(23):6976-6985. doi: 10.1158/1078-0432.CCR-19-1338. Epub 2019 Sep 3. Clin Cancer Res. 2019. PMID: 31481511 Free article. Clinical Trial.
68 results